Pfizer and BioNTech COVID-19 vaccine more than 90% effective in early analysis

Published



Pfizer and BioNTech announced Monday morning that one of its vaccine candidates has a more than 90% effectiveness in preventing COVID-19.

“Today is a great day for science and humanity,” said Pfizer CEO Alberta Bourla. “The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19.”

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.